The present invention provides heterocyclic compounds of formula (I), which are therapeutically useful as CBP/EP300 inhibitors. These compounds are useful in the treatment and/or prevention of diseases or disorders mediated by CBP and/or EP300 in an individual. The present invention also provides preparation of the ...

The present invention provides 6-substituted pyridazine compounds of formula (I), which are therapeutically useful as SMARCA2 and/or SMARCA4 degraders. These compounds are useful in the treatment and/or delaying progression of diseases or disorders dependent upon SMARCA2 and/or SMARCA4 in a subject. The present inve...

The present invention relates to the derivatives of compound of formula (I) and pharmaceutically acceptable salts thereof. The present invention further provides the methods of preparation of compound of formula (I) and use thereof as PRMT5 inhibitors. The compounds are useful as medicaments in the treatment of cond...

The present invention relates to a composition comprising of a CD47-SIRPa blocking agent and one or more anti-cancer agent(s): wherein the CD47-SIRPa blocking agent is represented by compound of formula (I). The present invention also relates to a method of treating cancer in a subject by administering therapeutical...

The present invention is directed to compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof that is useful as MALT-1 inhibitors for the treatment of a disease or disorder dependent on MALT-1. The present invention also relates to a method of preparation of the compounds...

The present invention provides fused benzoisoxazolyl compounds represented by compound of formula (I), which are therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of the diseases or disorders mediated by KAT6A in a subject. The present invention also provides preparation of t...

The present invention relates to the preparation of a CDK7 inhibitor having the structure of compound of formula (I). The invention described herein also relates to intermediates useful for preparing compound of formula (I) and methods of preparation of those intermediates.

The present invention provides a combination of a substituted heterocyclyl derivative of formula (I) or a pharmaceutically acceptable salt thereof which is a CDK7 inhibitor along with an anti-microtubule agent or prodrug thereof, and a method of treating or preventing cancer in a subject, comprising administering to...

The present invention is directed to compound of formula (I) and, a pharmaceutically acceptable salt or a stereoisomer thereof that useful as MALT-1 inhibitors for the treatment of diseases or disorders dependent on MALT-1. The present invention also relates to a method of preparation of the said compounds and pharm...

The present invention relates to compound of formula (I) fumarate and its crystalline form and methods of their preparation. (I) The invention also relates to preparations suitable for pharmaceutical uses for treatment of various diseases or disorders mediated by CDK7, particularly cancer or other proliferative dise...

PLEASE SEE THE ATTACHED SPECIFICATION

PLEASE SEE THE ATTACHED SPECIFICATION

The present invention provides fused isoxazolyl compound of formula (I), which are therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of diseases or disorders dependent upon KAT6A in a mammal. The present invention also provides preparation of the compounds and pharmaceutical ...

The present invention provides 3 substituted pyridazine compound of formula (I) which are therapeutically useful as SMARCA2 and/or SMARCA4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2 and/or SMARCA4 in a subject. The present invention also ...

The present application provides substituted N-(pyridin-2-yl)acetamide derivatives of formula (I), which are therapeutically useful as CDK12/13 inhibitors. These compounds are useful in the treatment and/or prevention of diseases and/or disorders associated with CDK12/13 in a mammal. In addition, the present applica...

The present invention relates to a compound of formula (I) wherein Z, M, R1, R2 and R3 are as defined in claim 1, or a pharmaceutically acceptable salt thereof. The compounds of formula (I) possess utility as inhibitors of Cbl-b. The compounds are useful as medicaments in the treatment of diseases or conditions wher...

The present invention provides tetracyclic compound of formula (I), which are therapeutically useful as SMARCA2 and/or SMARCA4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2 and/or SMARCA4 in a subject. The present invention also provides prep...

The present disclosure provides fused bicyclic heterocyclyl compounds and their derivatives of formula (I), which are therapeutically useful as CCR4 modulators. These compounds are useful in the treatment and/or prevention of diseases and/or disorders responsive to the modulation of CCR4 activity. Compounds of the p...